Metabolomic analysis of polar metabolites in lipoprotein fractions identifies lipoprotein-specific metabolic profiles and their association with insulin resistanceShow others and affiliations
2012 (English)In: Molecular Biosystems, ISSN 1742-206X, E-ISSN 1742-2051, Vol. 8, no 10, p. 2559-2565Article in journal (Refereed) Published
Abstract [en]
While the molecular lipid composition of lipoproteins has been investigated in detail, little is known about associations of small polar metabolites with specific lipoproteins. The aim of the present study was to investigate the profiles of polar metabolites in different lipoprotein fractions, i.e., very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL) and two sub-fractions of the high-density lipoprotein (HDL). The VLDL, IDL, LDL, HDL(2), and HDL(3) fractions were isolated from serum of sixteen individuals having a broad range of insulin sensitivity and characterized using comprehensive two-dimensional gas chromatography combined with time-of-flight mass spectrometry (GC×GC-TOFMS). The lipoprotein fractions had clearly different metabolite profiles, which correlated with the particle size and surface charge. Lipoprotein-specific associations of individual metabolites with insulin resistance were identified, particularly in VLDL and IDL fractions, even in the absence of such associations in serum. The results indicate that the polar molecules are strongly attached to the surface of the lipoproteins. Furthermore, strong lipoprotein-specific associations of metabolites with insulin resistance, as compared to their serum profiles, indicate that lipoproteins may be a rich source of tissue-specific metabolic biomarkers.
Place, publisher, year, edition, pages
Royal Society of Chemistry, 2012. Vol. 8, no 10, p. 2559-2565
National Category
Endocrinology and Diabetes Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Identifiers
URN: urn:nbn:se:oru:diva-63669DOI: 10.1039/c2mb25115aISI: 000308098600012PubMedID: 22722885Scopus ID: 2-s2.0-84865718863OAI: oai:DiVA.org:oru-63669DiVA, id: diva2:1169232
Funder
EU, FP7, Seventh Framework Programme, FP7-KBBE-222639, FP7-KBBE-222720
Note
Funding agencies:
Academy of Finland Centre of Excellence in Molecular Systems Immunology and Physiology Research-SyMMyS 250114
2017-12-222017-12-222019-03-04Bibliographically approved